HB 1296: Mental health; pilot program to support clinical research of certain veterans and first responders suffering from certain conditions; provide

In plain language

What the bill does

Who it affects

Why it matters

Key provisions

From the bill

Discussed in meetings (9)

The House and Senate meetings that took this bill up, from their machine transcripts. Each account was written by Georgia Commons with AI and is not part of the record; the video is what was said.

1. House floor session, February 18, 2026 (legislative day 20)

   From 0:32:56 · Watch on the General Assembly's Vimeo channel · Confirmed by the bill's status history (House Second Readers)

   Summary by Georgia Commons: The clerk gave HB 1296 a second reading as legislation concerning mental health. Later, the sponsor moved to transfer it from the Public Safety and Homeland Security Committee to the Defense and Veteran Affairs Committee, saying both committee chairs agreed. The House approved the transfer without objection. No discussion of the bill’s policy details occurred.

2. House Defense & Veterans Affairs Committee, February 24, 2026

   From 0:10:16 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: The sponsor said HB 1296 would establish a medically supervised pilot within the Department of Behavioral Health and Developmental Disabilities for veterans and retired first responders with PTSD, depression, traumatic brain injury and related conditions. The sponsor said it would begin in 2027 only if funded, end in 2030, support research and treatment access, and require annual reports. A witness for Veterans Exploring Treatment Solutions described psychedelic-assisted treatment and follow-up therapy. The witness cited research showing about 66% of MDMA-treated PTSD patients no longer met diagnostic criteria, compared with a 34% to 40% success rate for approved medications. One member supported the bill based on friends’ treatment experiences. Asked about costs, the sponsor’s presentation team estimated $1 million to $5 million. The witness estimated roughly 12 patients per $1 million and said ibogaine treatment lasts 16 to 22 hours. The chair requested a firmer funding estimate. Asked about eligibility, the witness described the nonprofit’s screening process, acknowledged risks and outlined preparation and follow-up, but did not establish the pilot’s selection rules. The sponsor said universities would be research partners. Although the chair initially framed the proposal as ibogaine-specific, another member questioned its broader language. The witness said researchers could select other qualifying treatments, and the sponsor supported flexibility. The committee adopted an amendment adding House and Senate veterans affairs committees as report recipients, then approved the amended bill by voice vote, without a stated count.

3. House Rules Committee, March 2, 2026

   From 0:53:45 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: The sponsor said HB 1296 would allow clinicians to use breakthrough treatments for veterans and public safety workers with post-traumatic stress disorder or traumatic brain injuries. Asked for an example, the sponsor named ibogaine-assisted therapy and said research universities would participate. The sponsor cited an approximately 84% effectiveness rate in treatments elsewhere, while saying the treatment was not a cure. A committee member asked whether psychedelics were included and whether FDA approval was required. The sponsor said eligible psychedelics would be included as they became FDA-approved. No decision was recorded.

4. House floor session, March 4, 2026 (legislative day 27, PM, part 1)

   From 3:10:12 · Watch on the General Assembly's Vimeo channel · Confirmed by the 2026 House Journal, p. 1919

   Summary by Georgia Commons: The sponsor said the bill would create a three-year, funding-dependent pilot program within the Department of Behavioral Health and Developmental Disabilities for veterans and retired first responders with conditions such as post-traumatic stress disorder, traumatic brain injury and treatment-resistant depression. The sponsor described physician-supervised treatments including magnetic brain stimulation, ibogaine-based therapies and other eligible treatments, with research data and annual legislative reports. The sponsor said it would not legalize recreational drugs or bypass the FDA. Asked about access, the sponsor said approved sites would typically connect with universities and serve people statewide. A member questioned coordination with existing VA care and funding. The sponsor said the program would use different funds and offer options after ordinary treatment fails, citing an 84% effectiveness figure without further detail. Asked how success would be measured, the sponsor said university researchers would collect and review Georgia-specific data, without naming measures. During voting, one member cited veteran suicide figures; another, identifying as a biomedical researcher, said new studies take about ten years. The House adopted the committee substitute and passed the bill 169-0.

5. House Rules Committee, March 4, 2026

   From 0:35:45 · Watch on the General Assembly's Vimeo channel · Confirmed by the 2026 House Journal, p. 1881

   Summary by Georgia Commons: The committee added HB 1296 to the day's supplemental calendar under modified structured rules without stated opposition. No provisions were discussed.

6. Senate Health and Human Services Committee, March 25, 2026

   From 0:20:00 · Watch on the General Assembly's Vimeo channel

   Summary by Georgia Commons: The chair said the sponsor requested more time to work on the bill and removed it from the agenda. No presentation or vote followed.

• Read aloud: House floor session, February 17, 2026 (legislative day 19), 0:48:49
• Read aloud: House floor session, February 25, 2026 (legislative day 24), 0:44:19
• Read aloud: Senate floor session, March 6, 2026 (legislative day 28, part 1), 0:40:30

Status timeline

Sponsors

Votes

Topics